Singapore Updates SaMD Guidance: Strengthening Oversight for AI-Enabled Medical Software

Singapore’s Health Sciences Authority (HSA) has released Revision 4 of its Guidance on Software Medical Devices (GL-04), introducing updated regulatory expectations for Software as a Medical Device (SaMD), including artificial intelligence (AI) and machine learning (ML)-enabled technologies.

The revised guidance reflects the rapid growth of digital health solutions and aims to ensure that regulatory oversight keeps pace with emerging software-driven medical technologies.

With healthcare increasingly powered by algorithms, connected platforms, and data-driven tools, regulators worldwide are refining frameworks to ensure safety, transparency, and performance throughout the product lifecycle.

Strengthening Regulatory Clarity for Software Medical Devices

The updated GL-04 guidance provides clearer direction on how software-based medical technologies should be regulated in Singapore. It reinforces that software intended for medical purposes, including standalone digital tools and AI-driven applications, falls under the country’s medical device regulatory framework.

By refining definitions and regulatory expectations, HSA aims to ensure consistent oversight while supporting continued innovation within the digital health sector.

Key Areas Addressed in the Updated Guidance

Several important areas have been strengthened in the revised framework.

Lifecycle Management of Software

The guidance emphasises the importance of structured lifecycle management for software medical devices. Developers are expected to maintain clear processes covering design, development, verification, validation, updates, and ongoing performance monitoring.

AI and Machine Learning Considerations

As AI-enabled medical technologies become more common, the updated guidance clarifies expectations for systems that rely on machine learning algorithms. This includes considerations around model transparency, performance validation, and mechanisms for managing algorithm updates.

Cybersecurity and Software Safety

Given the increasing connectivity of digital health products, the guidance highlights the need for robust cybersecurity measures. Manufacturers must ensure that appropriate safeguards are in place to protect patient data and prevent vulnerabilities that could compromise device safety or performance.

Alignment with International Regulatory Practices

Singapore continues to align its regulatory framework with international standards and guidance, including principles developed by global regulatory forums. This approach helps facilitate international cooperation and supports companies seeking to commercialise products across multiple markets.

Why This Matters for Industry

The updated SaMD guidance reflects the growing importance of digital technologies in modern healthcare and signals Singapore’s commitment to maintaining a forward-looking regulatory environment.

For manufacturers and developers, the update highlights the need to integrate regulatory considerations early in the software development process. Companies working with AI-driven or connected health technologies must ensure that documentation, validation strategies, and risk management processes meet evolving regulatory expectations.

Early alignment with these requirements can help streamline regulatory submissions and support smoother market entry.

A Broader Trend in Digital Health Regulation

Singapore’s revised guidance is part of a wider global movement toward stronger governance of digital health technologies. Regulators across major markets are increasingly focusing on the unique challenges posed by software-based medical devices, particularly those powered by artificial intelligence.

By strengthening oversight while encouraging responsible innovation, regulatory authorities aim to balance patient safety with technological advancement.

ARQon Perspective

As digital health technologies continue to reshape healthcare delivery, regulatory frameworks must evolve to ensure that innovation remains safe, reliable, and trustworthy.

Singapore’s updated SaMD guidance represents another step toward clearer governance of AI-enabled medical software and reinforces the country’s position as a leading regulatory hub for medical technology in Asia.

At ARQon, we continue to monitor regulatory developments across global markets to help organisations navigate evolving compliance landscapes and successfully bring innovative healthcare technologies to patients worldwide.